ACPU
RARE icon

Arrowgrass Capital Partners (US)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-20,000
Closed -$2.05M – 514
2015
Q2 		$2.05M Buy
+20,000
New +$1.55M 0.03% 331

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s RARE Position: Q3 2015 in Review

Arrowgrass Capital Partners (US) sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2015, closing a stake of 20,000 shares — an estimated $2.05M sold.

Arrowgrass Capital Partners (US) first reported a position in RARE in Q2 2015 and held it in 1 quarter. The position peaked at $2.05M in Q2 2015. 161 funds tracked by Wall St. Rank hold RARE as of Q3 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Ultragenyx Pharmaceutical position as of Q3 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 20,000 Ultragenyx Pharmaceutical shares in Q3 2015, an estimated $2.05M.
  • Arrowgrass Capital Partners (US) first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Ultragenyx Pharmaceutical position peaked at $2.05M in Q2 2015.
  • 161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2015, filed 16 Nov 2015.